450 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment...
New launch tracking reports and patient audit data show early excitement and ample opportunity for the latest approvals as well...
By: Eric John Pandemic aside (if you can imagine that), launching a drug in the pharmaceutical industry is no walk...
Authors: Maxine Yarnall, Tucker Hurtado, Vibeke Strand BACKGROUND and AIMS: present significant challenges in management. This study was to...
Authors: Maxine Yarnall BACKGROUND and AIMS: Treatment for psoriatic arthritis (PsA) is largely accounted for by TNFs and their...
Authors: Maxine Yarnall, Chrystal Ferguson BACKGROUND and AIMS: As use of Januse Kinase Inhibitor (JAKi) therapies in rheumatoid arthritis...
From: FiercePharma By: Angus Liu A recent survey of 100 high-volume U.S. rheumatologists that Piper Sandler conducted with Spherix...
From: FiercePharma By: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day...
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat,...
By: Maxine Yarnall There’s a reason why Spherix focuses on the new start and switching patient populations within the indications...
US dermatologists report increased confidence in treating psoriatic arthritis patients without a rheumatologist, and the two specialist groups report different...
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...
